All In Biotech

Drug Trial Radar · NCT06672900

A Multi-part Study of ALG-000184 to Evaluate Safety, Tolerability, Pharmacokinetics and Drug-drug Interaction Potential After Single and Multiple Doses in Healthy Volunteers

A Multi-Part Phase 1 Study in Healthy Volunteers to Evaluate the Drug-Drug Interaction Potential of Multiple Doses of ALG-000184.

Last checked: Nov 19, 2026Latest source record: Feb 3, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

24

Actual

Start

Jan 9, 2025

Primary completion

Jul 7, 2025

Study completion Jul 7, 2025

Sponsor

Lead sponsor
Aligos TherapeuticsIndustry
Sponsor type
Industry
First posted
Nov 4, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Other
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This Phase 1 study consists of two parts, all conducted in healthy volunteers (HVs). In Part 1, the drug-drug interaction (DDI) potential of ALG-000184 will be explored with Itraconazole; participants will be assigned to receive multiple doses of ALG-000184 and Itraconazole over a two week period. In Part 2, the drug-drug interaction (DDI) potential of ALG-000184 will be explored with Carbamazepine; participants will be assigned to receive multiple doses of ALG-000184 and ascending doses of Carbamazepine over an 18 day period. The 2 parts may be conducted in parallel.

Conditions

  • Healthy Volunteer

Interventions

  • CarbamazepineDrug

    Commercially available supply.

  • Itraconazole (Sporanox)Drug

    Commercially available supply.

  • ALG-000184Drug

    Study Investigational Product

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Area under the concentration time curve [AUC]Time frame: Up to 24 days
  2. Area under the concentration time curve [AUC]Time frame: Up to 29 days.
  3. Time to maximum plasma concentration [Tmax]Time frame: Up to 29 days
  4. Time to maximum plasma concentration [Tmax]Time frame: Up to 24 days
  5. Maximum plasma concentration [Cmax]Time frame: Up to 29 days
  6. Maximum plasma concentration [Cmax]Time frame: Up to 24 days
  7. Minimum plasma concentration [Cmin]Time frame: Up to 24 days
  8. Minimum plasma concentration [Cmin]Time frame: Up to 29 days
  9. C0 [predose]Time frame: Up to 24 days
  10. C0 [predose]Time frame: Up to 29 days
  11. Half-life [t1/2]Time frame: Up to 24 days
  12. Half-life [t1/2]Time frame: Up to 29 days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • PPD Austin Research Unit

    Austin, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.